Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CCR1 | P32246 | 1/20 | 0.78 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.74 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528053 | 0.91 | CCR1 (0.83) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL8738060 | 0.91 | CYP1A2 (1.00) | CYP1A2CCR1FERMT2NR4A2KDM4E | |
| SCHEMBL11757988 | 0.90 | CCR1 (0.86) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL10179919 | 0.89 | CCR1 (0.75) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL23883151 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL11756506 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL11758461 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL12223755 | 0.88 | CYP1A2 (0.77) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| Hydrochloric Acid SCHEMBL11758124 | 0.88 | CCR1 (0.82) | CYP1A2CCR1FERMT2NR4A2CDK1 | |
| SCHEMBL13735646 | 0.86 | CDK1 (0.77) | CYP1A2CCR1FERMT2NR4A2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285781-B | Preparation method of cilastatin sodium key intermediate | 鲁南制药集团股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-113512001-A | Preparation method of hydroxychloroquine | 浙江苏泊尔制药有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3848355-A1 | ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY | The Trustees Of The University Of Pennsylvania (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-2890981-B1 | SENESCENCE TRACERS | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2018-11-07 | — | — | EP | disclosed |
| US-9829481-B2 | Senescence tracers | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9829481-B2 | Senescence tracers | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20150168374-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150168374-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2015-06-18 | — | — | US | disclosed |
| WO-2014032737-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| CN-1130345-C | Amino quinoline derivatives | HOFFMANN LA ROCHE (CH) | 2003-12-10 | — | — | CN | disclosed |
| CN-1245168-A | Amino quinoline derivatives | HOFFMANN LA ROCHE (CH) | 2000-02-23 | — | — | CN | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| CN-1106389-A | Aminoquinoline derivatives | HOFFMANN LA ROCHE (CH) | 1995-08-09 | — | — | CN | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
| US-5182275-A | Intermediates for memory enhancers | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-01-26 | — | — | US | disclosed |
| US-4942168-A | INTERMEDIATES FOR 1,2-DIHYDRO-3-METHYL-3H-1,4-OXAZINO 2,3-C!QU INOLINE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0299345-A2 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | CYP1A2 446/4885CCR1 3594/4885FERMT2 3817/4885 |
| US-20150168374-A1 | SENESCENCE TRACERS | AGER, FUCA1, FUCA2 | CYP1A2 3628/4885CCR1 4752/4885FERMT2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.